Cited by 1,139RNA Interference and Gene DeliveryNanoparticle-Based Drug DeliveryRNA and protein synthesis mechanisms

The DOI matches its Crossref record; 105 of the 105 references it cites were found in a registry or an index.

Overcoming cellular barriers for RNA therapeutics

Dowdy, Steven F·2017·Nature Biotechnology

Open this paper in CoChat — free account

Abstract

RNA-based therapeutics, such as small-interfering (siRNAs), microRNAs (miRNAs), antisense oligonucleotides (ASOs), aptamers, synthetic mRNAs and CRISPR-Cas9, have great potential to target a large part of the currently undruggable genes and gene products and to generate entirely new therapeutic paradigms in disease, ranging from cancer to pandemic influenza to Alzheimer's disease. However, for these RNA modalities to reach their full potential, they first need to overcome a billion years of evolutionary defenses that have kept RNAs on the outside of cells from invading the inside of cells. Overcoming the lipid bilayer to deliver RNA into cells has remained the major problem to solve for widespread development of RNA therapeutics, but recent chemistry advances have begun to penetrate this evolutionary armor.

Integrity signals

Registry

Crossref · 10.1038/nbt.3802

Cites

105 of 105 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings 1PII of original article: S0169-409X(96)00423-1. The article was originally published in Advanced Drug Delivery Reviews 23 (1997) 3–25. 1
Lipinski, C. A., Lombardo, F., Dominy, B. W., & Feeney, P. J. (2001) · Advanced Drug Delivery Reviews · doi:10.1016/s0169-409x(00)00129-0 · Cited by 18,139
A Programmable Dual-RNA–Guided DNA Endonuclease in Adaptive Bacterial Immunity
Jinek, M., Chylinski, K., Fonfara, I., Hauer, M., Doudna, J. A., & Charpentier, E. (2012) · Science · doi:10.1126/science.1225829 · Cited by 17,116
Potent and specific genetic interference by double-stranded RNA in Caenorhabditis elegans
Fire, A., Xu, S., Montgomery, M. K., Kostas, S. A., Driver, S. E., & Mello, C. C. (1998) · Nature · doi:10.1038/35888 · Cited by 15,429
Multiplex Genome Engineering Using CRISPR/Cas Systems
Cong, L., Ran, F. A., Cox, D., Lin, S., Barretto, R., Habib, N., Hsu, P. D., Wu, X., Jiang, W., Marraffini, L. A., et al. (2013) · Science · doi:10.1126/science.1231143 · Cited by 15,339
Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells
Elbashir, S. M., Harborth, J., Lendeckel, W., Yalcin, A., Weber, K., & Tuschl, T. (2001) · Nature · doi:10.1038/35078107 · Cited by 9,456
RNA-Guided Human Genome Engineering via Cas9
Mali, P., Yang, L., Esvelt, K. M., Aach, J., Guell, M., DiCarlo, J. E., Norville, J. E., & Church, G. M. (2013) · Science · doi:10.1126/science.1232033 · Cited by 9,210
A new concept for macromolecular therapeutics in cancer chemotherapy: mechanism of tumoritropic accumulation of proteins and the antitumor agent smancs.
Matsumura, Y., & Maeda, H. (1986) · PubMed · Cited by 6,781
Direct Gene Transfer into Mouse Muscle in Vivo
Wolff, J. A., Malone, R. W., Williams, P., Chong, W., Acsadi, G., Jani, A., & Felgner, P. L. (1990) · Science · doi:10.1126/science.1690918 · Cited by 4,173
Mechanisms of endocytosis
Doherty, G. J., & McMahon, H. T. (2009) · Annual Review of Biochemistry · doi:10.1146/annurev.biochem.78.081307.110540 · Cited by 3,075
In vivo genome editing using Staphylococcus aureus Cas9
Ran, F. A., Cong, L., Yan, W. X., Scott, D. A., Gootenberg, J. S., Kriz, A. J., Zetsche, B., Shalem, O., Wu, X., Makarova, K. S., et al. (2015) · Nature · doi:10.1038/nature14299 · Cited by 2,687

Flagged first, then by citations

Show all 105 references

Research works printed but not linked: 2

Rich, A. in Horizons In Biochemistry (eds. Kasha, M. & Pullman, B.) 103–126 (Academic Press, New York, 1962).
Cummings, R. & McEver, R. in Essentials of Glycobiology. 2nd edn. (eds. Varki, A. et al.) Chapter 31 (Cold Spring Harbor (NY); Cold Spring Harbor Laboratory Press, 2009).

Sorted by citations

Items 501–600 of 1,000

Addressing cancer signal transduction pathways with antisense and siRNA oligonucleotides
Juliano, R. L. (2020) · NAR Cancer · doi:10.1093/narcan/zcaa025 · Cited by 27
Clinical Progress in Hepatic Targeting for Novel Prophylactic Therapies in Hereditary Angioedema
Riedl, M. A., Bordone, L., Revenko, A. S., Newman, K. B., & Cohn, D. M. (2023) · The Journal of Allergy and Clinical Immunology In Practice · doi:10.1016/j.jaip.2023.12.025 · Cited by 22
An Updated Analysis of Exon-Skipping Applicability for Duchenne Muscular Dystrophy Using the UMD-DMD Database
Leckie, J., Zia, A., & Yokota, T. (2024) · Genes · doi:10.3390/genes15111489 · Cited by 22
Hybrid Extracellular Vesicles for Efficient Loading and Functional Delivery of mRNA
Wang, X., Munson, M. J., Friis, K. P., Marzeda, A. M., da Silva, A. M., Kohl, F., Hultin, L., Schiffelers, R. M., & Dekker, N. (2025) · Journal of Extracellular Vesicles · doi:10.1002/jev2.70201 · Cited by 22
Ultrasound-Targeted Delivery Technology: A Novel Strategy for Tumor- Targeted Therapy
Du, M., Chen, Z., Chen, Y., & Li, Y. (2018) · Current Drug Targets · doi:10.2174/1389450119666180731095441 · Cited by 22
ATP7B variant c.1934T > G p.Met645Arg causes Wilson disease by promoting exon 6 skipping
Merico, D., Spickett, C., O’Hara, M., Kakaradov, B., Deshwar, A. G., Fradkin, P., Gandhi, S., Gao, J., Grant, S., Kron, K. J., et al. (2020) · npj Genomic Medicine · doi:10.1038/s41525-020-0123-6 · Cited by 25
Function and Therapeutic Implications of tRNA Derived Small RNAs
Wilson, B., & Dutta, A. (2022) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2022.888424 · Cited by 22
Cerebral Organoids and Antisense Oligonucleotide Therapeutics: Challenges and Opportunities
Lange, J., Zhou, H., & McTague, A. (2022) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2022.941528 · Cited by 22
In silico prediction of siRNA ionizable-lipid nanoparticles In vivo efficacy: Machine learning modeling based on formulation and molecular descriptors
Metwally, A. A., Nayel, A. A., & Hathout, R. M. (2022) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2022.1042720 · Cited by 22
Regulation of Protein Conformation Enables Cell‐Selective Targeting of Virus‐Mimicking Nanoparticles for siRNA Therapy of Glioblastoma
Zhu, H., Wang, Y., Wang, Z., Pang, D., & Liu, S. (2024) · Advanced Materials · doi:10.1002/adma.202401640 · Cited by 21
Invention and Early History of Exon Skipping and Splice Modulation
Lim, K. R. Q., & Yokota, T. (2018) · Methods in molecular biology · doi:10.1007/978-1-4939-8651-4_1 · Cited by 23
Codelivery of a cytotoxin and photosensitiser via a liposomal nanocarrier: a novel strategy for light-triggered cytosolic release
Yaghini, E., Dondi, R., Edler, K. J., Loizidou, M., MacRobert, A. J., & Eggleston, I. M. (2018) · Nanoscale · doi:10.1039/c8nr04048f · Cited by 22
Multivalent Peptide-Functionalized Bioreducible Polymers for Cellular Delivery of Various RNAs
Yang, D., Eldredge, A. C., Hickey, J. C., Muradyan, H., & Guan, Z. (2020) · Biomacromolecules · doi:10.1021/acs.biomac.0c00211 · Cited by 22
Absolute Quantification of Drug Vector Delivery to the Cytosol
Lucchino, M., Billet, A., Bai, S., Dransart, E., Hadjerci, J., Schmidt, F., Wunder, C., & Johannes, L. (2021) · Angewandte Chemie International Edition · doi:10.1002/anie.202102332 · Cited by 24
Vutrisiran: a new drug in the treatment landscape of hereditary transthyretin amyloid polyneuropathy
Planté‐Bordeneuve, V., & Perrain, V. (2024) · Expert Opinion on Drug Discovery · doi:10.1080/17460441.2024.2306843 · Cited by 21
Oligonucleotides: evolution and innovation
Mohammed, A. A., Shaer, D. A., & Musaimi, O. A. (2024) · Medicinal Chemistry Research · doi:10.1007/s00044-024-03352-7 · Cited by 24
Adverse immunological responses against non-viral nanoparticle (NP) delivery systems in the lung
de Braganca, L., Ferguson, G. J., Santos, J. L., & Derrick, J. P. (2021) · Journal of Immunotoxicology · doi:10.1080/1547691x.2021.1902432 · Cited by 24
A nanoconfined loading strategy for highly efficient siRNA delivery and cancer therapy
Zhang, W., Zhang, Y., Luo, Y., Chen, S., Huang, Q., Cao, Z., Ming, L., & Yang, X. (2022) · Nano Today · doi:10.1016/j.nantod.2022.101418 · Cited by 21
Research progress on non-protein-targeted drugs for cancer therapy
Zhang, Y., Lu, L., Song, F., Zou, X., Liu, Y., Zheng, X., Qian, J., Gu, C., Huang, P. C., & Yang, Y. (2023) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-023-02635-y · Cited by 22
Antisense Therapy for Infectious Diseases
Buthelezi, L. A., Pillay, S., Ntuli, N., Gcanga, L., & Guler, R. (2023) · Cells · doi:10.3390/cells12162119 · Cited by 21
Incorporation of poly(γ-glutamic acid) in lipid nanoparticles for enhanced mRNA delivery efficiency in vitro and in vivo
Zhang, H., Gao, X., Sun, Q., Dong, X., Zhu, Z., & Yang, C. (2024) · Acta Biomaterialia · doi:10.1016/j.actbio.2024.02.004 · Cited by 21
Strategies for enhanced gene delivery to the central nervous system
Gao, Z. (2024) · Nanoscale Advances · doi:10.1039/d3na01125a · Cited by 26
Cholesterol–GalNAc Dual Conjugation Strategy for Reducing Renal Distribution of Antisense Oligonucleotides
Wada, F., Yamamoto, T., Ueda, T., Sawamura, M., Wada, S., Harada‐Shiba, M., & Obika, S. (2018) · Nucleic Acid Therapeutics · doi:10.1089/nat.2017.0698 · Cited by 23
Hydrogel‐Induced Cell Membrane Disruptions Enable Direct Cytosolic Delivery of Membrane‐Impermeable Cargo
Hoeck, J. V., de Vyver, T. V., Harizaj, A., Goetgeluk, G., Merckx, P., Liu, J., Wels, M., Sauvage, F., Keersmaecker, H. D., Vanhove, C., et al. (2021) · Advanced Materials · doi:10.1002/adma.202008054 · Cited by 21
Kinetics of lipid-nanoparticle-mediated intracellular mRNA delivery and function
Zhdanov, V. P. (2017) · Physical review. E · doi:10.1103/physreve.96.042406 · Cited by 21
Evolution of antisense oligonucleotides: navigating nucleic acid chemistry and delivery challenges
Ruchi, R., Raman, G. M., Kumar, V., & Bahal, R. (2024) · Expert Opinion on Drug Discovery · doi:10.1080/17460441.2024.2440095 · Cited by 24
The Effects of Single Nucleotide Polymorphisms in Cancer RNAi Therapies
Gebert, M., Jaśkiewicz, M., Moszyńska, A., Collawn, J. F., & Bartoszewski, R. (2020) · Cancers · doi:10.3390/cancers12113119 · Cited by 22
Gene Modulation with CRISPR-based Tools in Human iPSC-Cardiomyocytes
Han, J., & Entcheva, E. G. (2023) · Stem Cell Reviews and Reports · doi:10.1007/s12015-023-10506-4 · Cited by 23
Future directions for medicinal chemistry in the field of oligonucleotide therapeutics
Hall, J. (2023) · RNA · doi:10.1261/rna.079511.122 · Cited by 21
Edge Length-Programmed Single-Stranded RNA Origami for Predictive Innate Immune Activation and Therapy
Dai, K., Xu, Y. Y., Yang, Y., Shen, J., Liu, X., Tu, X., Lu, Y., Qi, X., Li, J., Wang, L., et al. (2023) · Journal of the American Chemical Society · doi:10.1021/jacs.3c03477 · Cited by 20
A review of RNA nanoparticles for drug/gene/protein delivery in advanced therapies: Current state and future prospects
Vosoughi, P., Naghib, S. M., Kangarshahi, B. M., & Mozafari, M. R. (2025) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2025.139532 · Cited by 23
Multivalent ligand-receptor-mediated interaction of small filled vesicles with a cellular membrane
Zhdanov, V. P. (2017) · Physical review. E · doi:10.1103/physreve.96.012408 · Cited by 20
Non-protein biologic therapeutics
Sharfstein, S. T. (2017) · Current Opinion in Biotechnology · doi:10.1016/j.copbio.2017.12.014 · Cited by 20
Intracellular RNA delivery by lipid nanoparticles: Diffusion, degradation, and release
Zhdanov, V. P. (2019) · Biosystems · doi:10.1016/j.biosystems.2019.104032 · Cited by 21
miRNA packaging into small extracellular vesicles and implications in pain
DaCunza, J., Wickman, J. R., & Ajit, S. K. (2024) · PAIN Reports · doi:10.1097/pr9.0000000000001198 · Cited by 21
Peptide-based nanomaterials for gene therapy
Zhang, W., Chen, Q., Wu, F., Dai, J., Ding, D., Wu, J., Lou, X., & Xia, F. (2020) · Nanoscale Advances · doi:10.1039/d0na00899k · Cited by 20
Hydrophobic Optimization of Functional Poly(TPAE-co-suberoyl chloride) for Extrahepatic mRNA Delivery following Intravenous Administration
Yu, X., Liu, S., Cheng, Q., Lee, S. M., Wei, T., Zhang, D., Farbiak, L., Johnson, L. T., Wang, X., & Siegwart, D. J. (2021) · Pharmaceutics · doi:10.3390/pharmaceutics13111914 · Cited by 20
High density lipoprotein nanoparticle as delivery system for radio-sensitising miRNA: An investigation in 2D/3D head and neck cancer models
Dehghankelishadi, P., Maritz, M. F., Badiee, P., & Thierry, B. (2022) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2022.121585 · Cited by 19
Microinjection of antisense oligonucleotides into living mouse testis enables lncRNA function study
Chen, Z., Ling, L., Shi, X., Li, W., Zhai, H., Kang, Z., Zheng, B., Zhu, J., Ye, S., Wang, H., et al. (2021) · Cell & Bioscience · doi:10.1186/s13578-021-00717-y · Cited by 19
Current knowledge on the tissue distribution of mRNA nanocarriers for therapeutic protein expression
Zadory, M., Lopez, E., Babity, S., Gravel, S., & Brambilla, D. (2022) · Biomaterials Science · doi:10.1039/d2bm00859a · Cited by 18
Epigenetic Mechanisms Underlying Melanoma Resistance to Immune and Targeted Therapies
Rubanov, A., Berico, P., & Hernando, E. (2022) · Cancers · doi:10.3390/cancers14235858 · Cited by 23
siRNA-Based Novel Therapeutic Strategies to Improve Effectiveness of Antivirals: An Insight
Chatterjee, K., Lakdawala, S., Quadir, S. S., Puri, D., Mishra, D. K., Joshi, G., Sharma, S., & Choudhary, D. K. (2023) · AAPS PharmSciTech · doi:10.1208/s12249-023-02629-1 · Cited by 19
Synthesis of peptide–siRNA conjugates via internal sulfonylphosphoramidate modifications and evaluation of their in vitro activity
Smidt, J. M., Lykke, L., Stidsen, C. E., Pristovšek, N., & Gothelf, K. V. (2023) · Nucleic Acids Research · doi:10.1093/nar/gkad1015 · Cited by 18
Self-delivering, chemically modified CRISPR RNAs for AAV co-delivery and genome editing in vivo
Zhang, H., Kelly, K. L., Lee, J. L. C., Echeverria, D., Cooper, D., Panwala, R., Amrani, N., Chen, Z., Gaston, N., Wagh, A. A., et al. (2023) · Nucleic Acids Research · doi:10.1093/nar/gkad1125 · Cited by 19
Selective Intracellular Delivery of Antibodies in Cancer Cells with Nanocarriers Sensing Endo/Lysosomal Enzymatic Activity
Chen, P., Yang, W., Mochida, Y., Li, S., Hong, T., Kinoh, H., Kataoka, K., & Cabral, H. (2024) · Angewandte Chemie International Edition · doi:10.1002/anie.202317817 · Cited by 19
Lipopolymer mediated siRNA delivery targeting aberrant oncogenes for effective therapy of myeloid leukemia in preclinical animal models
Ansari, A. S., Remant, K. C., Morales, L. C., Nasrullah, M., Sundaram, D. N. M., Kucharski, C., Jiang, X., Brandwein, J. M., & Uludağ, H. (2024) · Journal of Controlled Release · doi:10.1016/j.jconrel.2024.02.018 · Cited by 19
Engineering of Erythrocytes as Drug Carriers for Therapeutic Applications
Jia, B., Shi, Y., Yan, Y., Shi, H., Zheng, J., & Liu, J. (2024) · Advanced Biology · doi:10.1002/adbi.202400242 · Cited by 19
Glioblastoma therapy: State of the field and future prospects
Khiabani, N. A., Doustvandi, M. A., Story, D. T., Nobari, S. A., Hajizadeh, M., Petersen, R. B., Dunbar, G. L., & Rossignol, J. (2024) · Life Sciences · doi:10.1016/j.lfs.2024.123227 · Cited by 21
siRNA-Encapsulated Biomimetic Liposomes Effectively Inhibit Tumor Cells’ Hexosamine Biosynthesis Pathway for Attenuating Hyaluronan Barriers to Pancreatic Cancer Chemotherapy
Wu, J., Cheng, Y., Qian, K., Yang, P., Zhou, L., Xu, M., Sheng, D., Wang, T., Li, Y., Yang, X., et al. (2025) · ACS Nano · doi:10.1021/acsnano.4c14969 · Cited by 19
Cancer Immunotherapy: Targeting Tumor-Associated Macrophages by Gene Silencing
Zins, K., & Abraham, D. (2020) · Methods in molecular biology · doi:10.1007/978-1-0716-0290-4_17 · Cited by 21
A critical approach for successful use of circulating microRNAs as biomarkers in cardiovascular diseases: the case of hypertrophic cardiomyopathy
Ntelios, D., Georgiou, E., Alexouda, S., Malousi, A., Efthimiadis, G. K., & Tzimagiorgis, G. (2021) · Heart Failure Reviews · doi:10.1007/s10741-021-10084-y · Cited by 21
Towards Self-Transfecting Nucleic Acid Nanostructures for Gene Regulation
Gudipati, S., Zhang, K., & Rouge, J. L. (2019) · Trends in biotechnology · doi:10.1016/j.tibtech.2019.01.008 · Cited by 19
Antisense and Functional Nucleic Acids in Rational Drug Development
Prof. Robert Penchovsky, D. R. N., Georgieva, A. V., Dyakova, V., Traykovska, M., & Pavlova, N. (2024) · Antibiotics · doi:10.3390/antibiotics13030221 · Cited by 19
Lysosome-associated CASM: from upstream triggers to downstream effector mechanisms
Kaur, N., Carlsson, S. R., & Lystad, A. H. (2025) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2025.1559125 · Cited by 19
C3AR1 mRNA as a Potential Therapeutic Target Associates With Clinical Outcomes and Tumor Microenvironment in Osteosarcoma
Zou, T., Liu, W., Wang, Z., Chen, J., Lu, S., Huang, K., & Li, W. (2021) · Frontiers in Medicine · doi:10.3389/fmed.2021.642615 · Cited by 18
A biodegradable amphiphilic poly(aminoester) dendrimer for safe and effective siRNA delivery
Ma, C., Zhu, D., Lin, W., Li, Y., Huang, Y., Zhu, H., Ye, M., Wang, Y., Peng, L., & Liu, X. (2022) · Chemical Communications · doi:10.1039/d1cc06655b · Cited by 18
Beyond GalNAc! Drug delivery systems comprising complex oligosaccharides for targeted use of nucleic acid therapeutics
O'Sullivan, J., Muñoz-Muñoz, J., Turnbull, G., Sim, N., Penny, S., & Moschos, S. A. (2022) · RSC Advances · doi:10.1039/d2ra01999j · Cited by 20
Co-Formulation of Amphiphilic Cationic and Anionic Cyclodextrins Forming Nanoparticles for siRNA Delivery in the Treatment of Acute Myeloid Leukaemia
Kont, A., Mendonça, M. C. P., Cronin, M. F., Cahill, M. R., & O’Driscoll, C. M. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23179791 · Cited by 19
Dual-functional extracellular vesicles enable synergistic treatment via m6A reader YTHDF1-targeting epigenetic regulation and chemotherapy
Du, R., You, Q., Liu, J., Wang, C., Zhu, L., & Yang, Y. (2023) · Nano Research · doi:10.1007/s12274-023-6105-0 · Cited by 19
Enhanced Intercellular Delivery of cRGD–siRNA Conjugates by an Additional Oligospermine Modification
Nakamoto, K., Akao, Y., Furuichi, Y., & Ueno, Y. (2018) · ACS Omega · doi:10.1021/acsomega.8b00850 · Cited by 17
Shifting Paradigms Revisited: Biotechnology and the Pharmaceutical Sciences
Crommelin, D. J. A., Mastrobattista, E., Hawe, A., Hoogendoorn, K. H., & Jiskoot, W. (2019) · Journal of Pharmaceutical Sciences · doi:10.1016/j.xphs.2019.08.010 · Cited by 20
Gene therapy with caspase-3 small interfering RNA-nanoparticles is neuroprotective after optic nerve damage
Tawfik, M., Zhang, X., Grigartzik, L., Heiduschka, P., Hintz, W., Henrich‐Noack, P., van Wachem, B., & Sabel, B. A. (2021) · Neural Regeneration Research · doi:10.4103/1673-5374.313068 · Cited by 18
Strategies and challenges for non-viral delivery of non-coding RNAs to the heart
Vilaça, A., Windt, L. J. D., Fernandes, H., & Ferreira, L. (2022) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2022.10.002 · Cited by 20
Ribonucleases as Drug Targets
Canestrari, E., & Paroo, Z. (2018) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2018.07.005 · Cited by 18
Regulation of fibroblast-like synoviocyte transformation by transcription factors in arthritic diseases
Bhattaram, P., & Jones, K. (2019) · Biochemical Pharmacology · doi:10.1016/j.bcp.2019.03.018 · Cited by 19
RNA Therapeutics (Almost) Comes of Age: Targeting, Delivery and Endosomal Escape
Dowdy, S. F., & Levy, M. (2018) · Nucleic Acid Therapeutics · doi:10.1089/nat.2018.29001.dow · Cited by 18
Self-citation
Advanced Carriers for Precise Delivery and Therapeutic Mechanisms of Traditional Chinese Medicines: Integrating Spatial Multi‐Omics and Delivery Visualization
Zhang, Y., Lü, Z., Guo, J., Wáng, Q., Zhang, X., Yang, H., & Li, X. (2025) · Advanced Healthcare Materials · doi:10.1002/adhm.202403698 · Cited by 19
Integration of metabolomic and transcriptomic analyses reveals regulatory functions of the ChREBP transcription factor in energy metabolism
An, J., Astapova, I. I., Zhang, G., Cangelosi, A. L., Ilkayeva, O., Marchuk, H., Muehlbauer, M. J., George, T., Brozinick, J. T., Herman, M. A., et al. (2025) · Cell Reports · doi:10.1016/j.celrep.2025.115278 · Cited by 17
Aptamer-based applications in delivering cancer gene therapies and beyond: state of the art and the missing links to clinical translation
Coppola, G., Cennamo, F., Ciccone, G., Ibba, M. L., Ruscio, A. D., Vito, A. D., Esposito, C. L., & Catuogno, S. (2025) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2025.115639 · Cited by 17
Cyclodextrins as Active Therapeutic Agents: Beyond Their Role as Excipients
Pîrvu, A. S., Văruţ, R.-M., Trașcă, D.-M., Stoica, G. A., Radivojević, K., Carmen, S., Arsenie, C. C., & Popescu, C. (2025) · Pharmaceuticals · doi:10.3390/ph18101592 · Cited by 22
Reactive oxygen species-responsive nanoplatforms for nucleic acid-based gene therapy of cancer and inflammatory diseases
Zhu, D., Chen, W., Lin, W., Li, Y., & Liu, X. (2021) · Biomedical Materials · doi:10.1088/1748-605x/ac0a8f · Cited by 17
Challenges and future perspective of antisense therapy for spinal muscular atrophy: A review
Nakevska, Z., & Yokota, T. (2023) · European Journal of Cell Biology · doi:10.1016/j.ejcb.2023.151326 · Cited by 18
A technology evaluation of the atypical use of a CPP-containing peptide in the formulation and performance of a clinical botulinum toxin product
Dowdy, S. F., Gallagher, C. J., Vitarella, D., & Brown, J. A. (2023) · Expert Opinion on Drug Delivery · doi:10.1080/17425247.2023.2251399 · Cited by 17
Self-citation
Engineering metabolism to modulate immunity
Kapnick, S. M., Martin, C. A., & Jewell, C. M. (2023) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2023.115122 · Cited by 18
In Situ Intracellular Autocatalytic Hairpin Assembly of the Y‑Shaped DNA Nanostructure for miR-155 Sensing and Gene Silencing
Zhou, S., Shan, F., Cao, Y., Huang, P., Yang, H., & Liu, S. (2024) · Analytical Chemistry · doi:10.1021/acs.analchem.4c02490 · Cited by 17
RNA-loaded nanoparticles for the treatment of hematological cancers
Garbayo, E., Moukhtari, S. H. E., Rodríguez‐Nogales, C., Agirre, X., Rodríguez-Madoz, J. R., Rodríguez-Márquez, P., Prósper, F., Couvreur, P., & Blanco‐Prieto, M. J. (2024) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2024.115448 · Cited by 19
Spatially Controlled Co‐Delivery of Diagnostic and Therapeutic Agents Using DNA Nanoframeworks for Pancreatic Cancer Precision Therapy
Song, N., Tao, R., Li, H., Zhang, R., Huang, Y., Zhang, L., Liu, Y., Yang, D., & Yao, C. (2025) · Angewandte Chemie International Edition · doi:10.1002/anie.202500566 · Cited by 17
Direct Cytosolic MicroRNA Detection Using Single-Layer Perfluorinated Tungsten Diselenide Nanoplatform
Song, Y., Yan, X., Ostermeyer, G. P., Li, S., Qu, L., Du, D., Li, Z., & Lin, Y. (2018) · Analytical Chemistry · doi:10.1021/acs.analchem.8b02193 · Cited by 17
Nanocarrier Lipid Composition Modulates the Impact of Pulmonary Surfactant Protein B (SP-B) on Cellular Delivery of siRNA
Guagliardo, R., Merckx, P., Zamborlin, A., Backer, L. D., Echaide, M., Pérez‐Gil, J., Smedt, S. C. D., & Raemdonck, K. (2019) · Pharmaceutics · doi:10.3390/pharmaceutics11090431 · Cited by 17
Chemical Modifications in RNA Interference and CRISPR/Cas Genome Editing Reagents
Lennox, K. A., & Behlke, M. A. (2020) · Methods in molecular biology · doi:10.1007/978-1-0716-0290-4_2 · Cited by 17
Folding heterogeneity in the essential human telomerase RNA three-way junction
Palka, C., Forino, N. M., Hentschel, J., Das, R., & Stone, M. D. (2020) · RNA · doi:10.1261/rna.077255.120 · Cited by 18
Disulfide‐Unit Conjugation Enables Ultrafast Cytosolic Internalization of Antisense DNA and siRNA
Shu, Z., Tanaka, I., Ota, A., Fushihara, D., Abe, N., Kawaguchi, S., Nakamoto, K., Tomoike, F., Tada, S., Ito, Y., et al. (2019) · Angewandte Chemie · doi:10.1002/ange.201900993 · Cited by 17
Cancer-cell-membrane-camouflaged supramolecular self-assembly of antisense oligonucleotide and chemodrug for targeted combination therapy
Chen, T., Xu, J., Zhu, L., & Yan, D. (2022) · Nanoscale · doi:10.1039/d2nr05669k · Cited by 17
Development of a detection method for antisense oligonucleotides in mouse kidneys by matrix‐assisted laser desorption/ionization imaging mass spectrometry
Yokoi, H., Kasahara, Y., Obika, S., Doi, T., & Kamada, H. (2018) · Rapid Communications in Mass Spectrometry · doi:10.1002/rcm.8274 · Cited by 17
Rigorous control of vesicle-forming lipid pKa by fluorine-conjugated bioisosteres for gene-silencing with siRNA
Okamoto, A., Koide, H., Morita, N., Hirai, Y., Kawato, Y., Egami, H., Hamashima, Y., Asai, T., Dewa, T., & Oku, N. (2018) · Journal of Controlled Release · doi:10.1016/j.jconrel.2018.12.044 · Cited by 17
Aptamers as the chaperones (Aptachaperones) of drugs-from siRNAs to DNA nanorobots
Citartan, M., Kaur, H., Presela, R., & Tang, T. (2019) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2019.118483 · Cited by 17
Matrix stiffness regulates lipid nanoparticle-mRNA delivery in cell-laden hydrogels
Athirasala, A., Patel, S., Menezes, P. P., Kim, J., Tahayeri, A., Sahay, G., & Bertassoni, L. E. (2022) · Nanomedicine: Nanotechnology, Biology and Medicine · doi:10.1016/j.nano.2022.102550 · Cited by 16
mRNA vaccine development and applications: A special focus on tumors (Review)
Chen, B., Yang, Y., Wang, X., Yang, W., Lu, Y., Wang, D., Zhuo, E., Tang, Y., Su, J., Tang, G., et al. (2024) · International Journal of Oncology · doi:10.3892/ijo.2024.5669 · Cited by 17
Programmable Circular Multivalent Nanobody‐Targeting Chimeras (mNbTACs) for Multireceptor‐Mediated Protein Degradation and Targeted Drug Delivery
Jiang, S., Lv, X., Ouyang, Z., Chi, H., Zeng, Y., Wang, Y., He, J., Chen, J., Chen, J., An, K., et al. (2024) · Angewandte Chemie International Edition · doi:10.1002/anie.202407986 · Cited by 19
General Platform for Efficient and Modular Assembly of GalNAc–siRNA Conjugates via Primary Amines and o-Nitrobenzyl Alcohol Cyclization Photoclick Chemistry Enabling Rapid Access to Therapeutic Oligonucleotides
Nie, H., Hu, H., Qi, X., Zhou, Y.-J., Liu, L., & Chen, X. (2025) · JACS Au · doi:10.1021/jacsau.5c00012 · Cited by 16
Engineered bacterial outer membrane vesicles enhanced tumor immunotherapy through remodeling tumor stroma and targeted delivery of CD73 siRNA
Cheng, L., Peng, D., Liu, Z., Tang, J., Zhang, P., Li, M., Li, J., Le, Z., & Liu, J. (2025) · Biomaterials · doi:10.1016/j.biomaterials.2025.123725 · Cited by 16
A novel aptamer-based small RNA delivery platform and its application to cancer therapy
Tanno, T., Zhang, P., Bailey, C. M., Wang, Y., Ittiprasert, W., Devenport, M., Zheng, P., & Liu, Y. (2022) · Genes & Diseases · doi:10.1016/j.gendis.2022.05.004 · Cited by 17
Cell-Derived Vesicles for mRNA Delivery
Li, Z., Liu, Z., Wu, J., & Li, B. (2022) · Pharmaceutics · doi:10.3390/pharmaceutics14122699 · Cited by 16
Iron Oxide Nanoparticle-Mediated siRNA Delivery System for Huntington’s Disease Treatment
Rohiwal, S. S., Nguyen, T. D., Kamenná, E., Klı́ma, J., Vaškovičová, M., Sekac, D., Šlouf, M., Pavlová, E., Stepanek, P., Babuka, D., et al. (2023) · ACS Applied Nano Materials · doi:10.1021/acsanm.2c03936 · Cited by 16
Localized chemotherapy approaches and advanced drug delivery strategies: a step forward in the treatment of peritoneal carcinomatosis from ovarian cancer
Breusa, S., Zilio, S., Catania, G., Bakrin, N., Kryza, D., & Lollo, G. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2023.1125868 · Cited by 17
Targeting triple-negative breast cancer cells with a β1-integrin binding aptamer
Pleiko, K., Haugas, M., Parfejevs, V., Panteļejevs, T., Parisini, E., Teesalu, T., & Riekstiņa, U. (2023) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2023.08.015 · Cited by 16
Insights into role of microRNA in Alzheimer's disease: From contemporary research to bedside perspective
Bandakinda, M., & Mishra, A. (2023) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2023.126561 · Cited by 16
Engineering endosomolytic nanocarriers of diverse morphologies using confined impingement jet mixing
Pagendarm, H. M., Stone, P. T., Kimmel, B. R., Baljon, J. J., Aziz, M. H., Pastora, L. E., Hubert, L., Roth, E. W., Almunif, S., Scott, E. A., et al. (2023) · Nanoscale · doi:10.1039/d3nr02874g · Cited by 16
Pulmonary fibroblast-specific delivery of siRNA exploiting exosomes-based nanoscaffolds for IPF treatment
Lu, H., Liu, X., Zhang, M., Bera, H., Xu, W., Jiang, H., Zhao, X., Wu, L., Cun, D., & Yang, M. (2024) · Asian Journal of Pharmaceutical Sciences · doi:10.1016/j.ajps.2024.100929 · Cited by 17
Revolutionizing mRNA Vaccines Through Innovative Formulation and Delivery Strategies
Fatima, M., An, T., & Hong, K. (2025) · Biomolecules · doi:10.3390/biom15030359 · Cited by 20

Authors: Dowdy, S. F.
Affiliations: University of California San Diego (US)
Corresponding author: Dowdy, Steven F
ORCID: Dowdy, Steven F
Venue: Nature Biotechnology
Publisher: Springer Science and Business Media LLC
Published: 2017-02-27
Volume: 35
Issue: 3
Pages: 222-229
ISSN: 0733-222X (ISSN-L)
1087-0156
1546-1696
DOI: 10.1038/nbt.3802
OpenAlex: W2594133976
Cited by: 1,139
References: 105
Citations by year: 2026: 103 · 2025: 130 · 2024: 147 · 2023: 133 · 2022: 130 · 2021: 141 · 2020: 104 · 2019: 88 · 2018: 120 · 2017: 41
FWCI: 9.04
Type: journal article
Language: en
Open access: closed
Licence: www.springer.com/tdm (tdm)
www.springer.com/tdm (vor)
Locations: Nature Biotechnology (publishedVersion)
PubMed (publishedVersion)
Topics: Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA Interference and Gene Delivery
Physical Sciences › Materials Science › Biomaterials › Nanoparticle-Based Drug Delivery
Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA and protein synthesis mechanisms
Keywords: RNA therapeutics, RNA delivery, lipid bilayers, siRNA, microRNA, antisense oligonucleotides, aptamers, synthetic mRNA, CRISPR/Cas9
MeSH terms: RNAi Therapeutics, Animals, Cell Membrane, Humans, RNA, RNA Interference, Nanocapsules, Molecular Targeted Therapy

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Overcoming cellular barriers for RNA therapeutics

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cites

Cited by

Related

Metadata

Record

About these checks